THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES

EHA Library, Adil Al Hinai, 181825

EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITETCURE IN MDS/AML

EHA Library, James Smith, 181826

NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA

EHA Library, I-Jun Lau, 181827

CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN ACUTE MYELOID LEUKAEMIA

EHA Library, Sneha CHITRE, 181828

TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML

EHA Library, Iris Uras, 181829

CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT.

EHA Library, Mayte Medrano, 181830

PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

EHA Library, Elisa Sala, 181831

AML PATIENTS AGED ≥75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?

EHA Library, Victoria Prassek, 181833

GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE

EHA Library, Daniel J. DeAngelo, 181834

BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY

EHA Library, Tsila Zuckerman, 181835

FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES

EHA Library, Claudia Haferlach, 181836

COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)

EHA Library, Kiyomi Morita, 181837

THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY

EHA Library, Daehun kwak, 181838

VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML

EHA Library, Eunice Wang, 181839

PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH '7+3' DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD

EHA Library, Dr. Medhavi Gupta, 181840

VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL.

EHA Library, Joan Ballesteros, 181841

RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS > 60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP

EHA Library, Haifa Kathrin Al-Ali, 181842

OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY

EHA Library, Jeffrey Lancet, 181843

HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA

EHA Library, Sarah Bertoli, 181844

NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE - IMPACT OF AGE ON MUTATIONAL LOAD

EHA Library, Lisa Pleyer, 181845

PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY

EHA Library, Sigrid Machherndl-Spandl, 181846

EVALUATION OF THE IMPACT OF SIGNAL RATIO ON OVERALL SURVIVAL IN FLT3-MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING ONCE-DAILY TREATMENT WITH GILTERITINIB

EHA Library, Mark J Levis, 181847

CLINICAL OUTCOME OF HYPOCELLULAR AML AND AML WITH MYELODYSPLASIA-RELATED CHANGE (MRC) COMPARED TO DE NOVO ADULT AML WITH NORMAL CELLULARITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Daehun kwak, 181848

INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML

EHA Library, Jorge Cortes, 181849

COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA

EHA Library, Matthew A. Lunning, 181850

VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Matthew S. Davids, 181851

WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA

EHA Library, Katja De Paepe, 181852

PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.

EHA Library, Joost Vermaat, 181854

HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY

EHA Library, Marcus Hentrich, 181855

RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA

EHA Library, Deok-Hwan Yang, 181856

LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES.

EHA Library, Francesca Farina, 181857

PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.

EHA Library, Catherine Scholz, 181858

BAM CONDITIONING BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (SFGM-TC).

EHA Library, Jérôme Jérôme, 181859

ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Raúl Teruel, 181860

SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA

EHA Library, Francesca Fioredda, 181862

TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS

EHA Library, Constantijn halkes, 181863

IMMUNE RECONSTITUTION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION

EHA Library, Pei Xuying, 181864

DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY

EHA Library, Mirkka Schaller, 181865

DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS.

EHA Library, Birgit van Dooijeweert, 181866

NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES

EHA Library, Eva Galvez, 181867

APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY

EHA Library, Emilie Nevill, 181868

RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 28 YEARS

EHA Library, Maren Oelmüller, 181869

NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS

EHA Library, Federico Pozzo, 181870

CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.

EHA Library, Julia Almeida, 181871

NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES

EHA Library, Andrejs Braun, 181872

MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Fortunato Morabito, 181873

IL-4 INCREASES EXPRESSION OF POSITIVE REGULATORS OF BCR SIGNALLING IN CLL WHICH CAN BE OVERCOME BY CERDULATINIB

EHA Library, Matthew Blunt, 181874

INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE

EHA Library, Erika Tissino, 181875

IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY

EHA Library, Talha Munir, 181876

EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53

EHA Library, Sean Post, 181877

THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA

EHA Library, Mhairi Copland, 181878

SIGNAL TRANSDUCING ADAPTOR PROTEIN-1 (STAP-1) MAINTAINS CHRONIC MYELOID LEUKEMIC STEM CELLS

EHA Library, Jun Toda, 181879

TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT

EHA Library, Anne-Sophie Bouillon, 181880

GENOMIC CHARACTERIZATION OF CML AT DIAGNOSIS REVEALS PREEXISTING SOMATIC MUTATIONS THAT MAY PREDICT PROGRESSION TO BLASTIC PHASE INDEPENDENTLY OF BCR-ABL1 MUTATIONS

EHA Library, Marcin Machnicki, 181881

INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE

EHA Library, Sieghart Sopper, 181882

BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB

EHA Library, Konstantin Byrgazov, 181883

IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO.

EHA Library, Robert Peter Gale, 181884

MUTATIONAL ANALYSIS IN BCR-ABL1 POSITIVE LEUKEMIA BY DEEP SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY

EHA Library, Francesco ALBANO, 181885

THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA.

EHA Library, Sara Galimberti, 181886

ROLE OF THE AURORA KINASE A/PLK 1 AXIS INHIBITION IN RESTORATION OF CELL GROWTH CONTROL OF CHRONIC MYELOID LEUKEMIA PROGENITORS

EHA Library, Manuela Mancini, 181887

DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE

EHA Library, David Ross, 181888

RESPONSE DIFFERENCES IN THE BCR-ABL1 E13A2 AND E14A2 VARIANTS MAY BE A TECHNICAL QPCR ARTIFACT

EHA Library, Niels Pallisgaard, 181889

5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)

EHA Library, Jorge Cortes, 181890

LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE

EHA Library, Monica Crugnola, 181891

IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY

EHA Library, Gabriele Gugliotta, 181892

ASSESSMENT OF CHRONIC RENAL INJURY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE RECEIVING TYROSINE KINASE INHIBITORS

EHA Library, Jiang Qian, 181893

COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY QPCR AND DIGITAL-PCR (DPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS

EHA Library, Simona Bernardi, 181894

OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA

EHA Library, Chetasi Talati, 181895

EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS

EHA Library, Juan Luis Steegmann, 181896

GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB

EHA Library, Giovanni Caocci, 181897

THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 VARIANT

EHA Library, Michal Gniot, 181898

ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA

EHA Library, Kei Saito, 181899

BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL.

EHA Library, Sigbjorn Berentsen, 181900

EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS.

EHA Library, R van Wijk, 181901

IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING

EHA Library, MARIA DEL MAR MANU PEREIRA, 181902

CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME

EHA Library, Bruno Fattizzo, 181903

HEME BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS INTERACTION WITH CELL MEMBRANE PHOSPHATIDYLSERINE DURING SICKLE CELL DISEASE

EHA Library, Sihem Sadoudi, 181904

USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY

EHA Library, Hemant Misra, 181905

NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN LEVELS IN SICKLE CELL DISEASE

EHA Library, Kate Gardner, 181906

THE PHARMACOKINETICS (PK) OF GBT440 ARE SIMILAR IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE (SCD)

EHA Library, Carla Washington, 181907

DEVELOPMENT OF TAX-REDIRECTED T-CELL IMMUNOTHERAPY FOR ADULT T CELL LEUKEMIA

EHA Library, Koji Kawamura, 181908

NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN FANCONI ANEMIA HEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Francisco J Roman-Rodriguez, 181910

NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES

EHA Library, Antonia , 181911

A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF HEMATOLOGICAL MALIGNANCIES AND CANCERS

EHA Library, Yasushi Kasahara, 181912

NKP30-CAR REDIRECTED HUMAN T LYMPHOCYTES INDUCE POTENT ANTITUMOR IMMUNITY TO LEUKEMIA CELL LINES AND PATIENT-DERIVED ACUTE MYELOID LEUKEMIA IN NSG XENOGRAFT MODELS

EHA Library, Udo Hartwig, 181913

PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANSFER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA

EHA Library, Hakim Echchannaoui, 181914

EXPLORING HUMAN TCR- AND CAR-REDIRECTED INKT CELLS FOR ADOPTIVE CELLULAR THERAPY

EHA Library, Udo Hartwig, 181916

SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR).

EHA Library, Maria Caterina Rotiroti, 181917

UPDATE ON THE FIRST PATIENTS WITH SEVERE HEMOGLOBINOPATHIES TREATED WITH LENTIGLOBIN GENE THERAPY

EHA Library, Marina Cavazzana, 181918

A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

EHA Library, Magali Van den Bergh, 181919

ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)

EHA Library, Andres Forero-Torres, 181920

PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS

EHA Library, John Burke, 181921

A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA

EHA Library, Michinori Ogura, 181922

DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND PUVA

EHA Library, Serena Rupoli, 181923

PHASE 3 ALCANZA STUDY OF BRENTUXIMAB VEDOTIN (BV) OR PHYSICIAN'S CHOICE (PC) OF METHOTREXATE (MTX) OR BEXAROTENE (BEX) IN CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA (CTCL):NUMBER NEEDED TO TREAT ANALYSIS

EHA Library, Mehul R. Dalal, 181924

PRIMARY OCULAR ADNEXAL LYMPHOMA OF ALL HISTOLOGIC SUBTYPES: SURVIVAL OUTCOMES ANDRISK FACTORS IN LARGE COHORT OF PATIENTS AND LONG-TERM FOLLOW-UP

EHA Library, Youngwoo Jeon, 181925

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES

EHA Library, Christina Kalpadakis, 181926

SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY

EHA Library, Carlos Panizo, 181927

REAL-WORLD EXPERIENCE WITH RITUXIMAB-FLUDARABINE (RF) AND DEXAMETHASONE, RITUXIMAB, CYCLOPHOSPHAMIDE (DRC) IN WALDENSTROM MACROGLOBULINEMIA : A RETROSPECTIVE STUDY FROM 163 PATIENTS

EHA Library, Caroline Protin, 181928

MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL

EHA Library, Tatsuo Oyake, 181929